Technetium tc 99m sestamibi
Technetium Tc-99m Sestamibi (technetium tc 99m sestamibi) is a small molecule pharmaceutical. Technetium tc 99m sestamibi was first approved as Technetium tc 99m sestamibi on 2008-09-22.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cardioite | 2006-02-22 | |
| cardiolite | New Drug Application | 2022-12-06 |
| kit for the preparation of technetium tc 99m sestamibi | ANDA | 2013-09-13 |
| kit for the preparation of technetium tc 99m sestamibi injection | ANDA | 2012-01-26 |
| kit for the preparation of technetium tc99m sestamibi | ANDA | 2024-09-10 |
| kit for the preparation of technetium tc99m sestamibi injection | ANDA | 2010-04-23 |
| sestamibi | unapproved drug other | 2012-05-23 |
| technetium tc 99m sestamibi | ANDA | 2022-05-19 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
63 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | — | 3 | 3 | 1 | 10 | 17 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | 1 | 1 | 4 | 6 |
| Primary hyperparathyroidism | D049950 | EFO_0008519 | E21.0 | — | — | 1 | 1 | 2 | 4 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | 2 | 3 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | 1 | 2 | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | 2 | 1 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | 1 | 2 |
| Hypercalcemia | D006934 | HP_0003072 | E83.52 | — | — | — | 1 | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | 1 | — | 1 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 3 | 3 | — | 7 | 13 |
| Coronary disease | D003327 | — | — | — | 2 | 3 | — | 4 | 9 |
| Parathyroid neoplasms | D010282 | — | — | — | 1 | 2 | — | 1 | 3 |
| Adenoma | D000236 | — | — | — | 1 | 2 | — | 1 | 3 |
| Parathyroid diseases | D010279 | — | E21.5 | — | — | 1 | — | 1 | 2 |
| Mucocutaneous lymph node syndrome | D009080 | EFO_0004246 | M30.3 | 1 | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | 2 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | 3 | 4 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 1 | — | — | 2 | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | 1 | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 1 | — | — | — | 2 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | — | — | — | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | 14 | 16 |
| Molecular imaging | D057054 | — | — | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | — | — | — | 2 | 2 |
| Chest pain | D002637 | HP_0100749 | R07.9 | — | — | — | — | 2 | 2 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
| Myocardial reperfusion | D015425 | — | — | — | — | — | — | 1 | 1 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | — | 1 | 1 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | — | — | — | 1 | 1 |
| Ventricular remodeling | D020257 | — | — | — | — | — | — | 1 | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
| Galactorrhea | D005687 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Technetium tc 99m sestamibi |
| INN | — |
| Description | Technetium (99mTc) sestamibi (INN) (commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined. The generic drug became available late September 2008. A scan of a patient using MIBI is commonly known as a "MIBI scan".
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 109581-73-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594241 |
| ChEBI ID | — |
| PubChem CID | 25199598 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 151 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
812 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use